This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Bupropion as an Antidote for Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction

Adam Keller Ashton and Raymond C. Rosen

Published: March 15, 1998

Article Abstract

Background: Serotonin reuptake inhibitingantidepressants (SRIs) are reported to cause sexual dysfunctions,including reduction in desire, arousal, and orgasm. This studyevaluates the efficacy of bupropion in ameliorating sexualdysfunctions in patients receiving SRIs.

Method: Forty-seven patients in an outpatientpsychiatric practice who complained of SRI-induced sexualdysfunction accepted a trial of bupropion as an adjunct to theirSRI, either as a p.r.n. or as a fixed-dose scheduled medicine.Patients received 75 mg or 150 mg of bupropion 1 to 2 hoursbefore sexual activity. If this was insufficient to reduce theircomplaints, dose was increased gradually to 75 mg t.i.d. andsustained for 2 weeks. This regimen was then continued ifsuccessful.

Results: Bupropion successfully reversed avariety of sexual dysfunctions caused by SRIs in 31 (66%) of 47patients. Fifty-two (69%) of 75 sexual complaints improved withbupropion treatment. The p.r.n. use of bupropion assisted 18(38%) of 47 patients. Side effects of anxiety and tremor led todiscontinuation of bupropion in 7 (15%) of 47 patients.Otherwise, bupropion was well tolerated.

Conclusion: Bupropion administration may be asafe and effective method of treating SRI-induced sexualdysfunction. Placebo-controlled, double-blind studies are needed.

Volume: 59

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF